Prot #TCD601B203: A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination with Belatacept and MPA Compared to Standard of Care Immunosuppression in de novo Renal Transplant Recipients (ASCEND)

Project: Research project

Project Details

StatusActive
Effective start/end date2/21/24 → 2/21/27

Funding

  • ITB-MED LLC (Prot #TCD601B203)